Trade PDS Biotechnology Corporation - PDSB CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
PDS Biotechnology Corp ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 5.27 |
Open* | 5.28 |
1-Year Change* | 60.98% |
Day's Range* | 5.12 - 5.28 |
52 wk Range | 2.89-13.65 |
Average Volume (10 days) | 361.09K |
Average Volume (3 months) | 14.04M |
Market Cap | 182.74M |
P/E Ratio | -100.00K |
Shares Outstanding | 30.87M |
Revenue | N/A |
EPS | -1.61 |
Dividend (Yield %) | N/A |
Beta | 1.92 |
Next Earnings Date | Nov 13, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 22, 2023 | 5.18 | -0.03 | -0.58% | 5.21 | 5.28 | 5.11 |
Sep 21, 2023 | 5.27 | 0.04 | 0.76% | 5.23 | 5.34 | 5.15 |
Sep 20, 2023 | 5.25 | -0.08 | -1.50% | 5.33 | 5.47 | 5.18 |
Sep 19, 2023 | 5.31 | -0.04 | -0.75% | 5.35 | 5.48 | 5.27 |
Sep 18, 2023 | 5.36 | 0.00 | 0.00% | 5.36 | 5.55 | 5.31 |
Sep 15, 2023 | 5.30 | -0.20 | -3.64% | 5.50 | 5.53 | 5.27 |
Sep 14, 2023 | 5.58 | 0.05 | 0.90% | 5.53 | 5.73 | 5.44 |
Sep 13, 2023 | 5.46 | -0.12 | -2.15% | 5.58 | 5.81 | 5.45 |
Sep 12, 2023 | 5.55 | -0.13 | -2.29% | 5.68 | 5.82 | 5.53 |
Sep 11, 2023 | 5.87 | 0.17 | 2.98% | 5.70 | 5.99 | 5.68 |
Sep 8, 2023 | 5.79 | 0.00 | 0.00% | 5.79 | 5.88 | 5.76 |
Sep 7, 2023 | 5.88 | 0.12 | 2.08% | 5.76 | 5.96 | 5.70 |
Sep 6, 2023 | 5.80 | -0.01 | -0.17% | 5.81 | 5.86 | 5.59 |
Sep 5, 2023 | 5.78 | -0.16 | -2.69% | 5.94 | 5.98 | 5.75 |
Sep 1, 2023 | 6.01 | 0.18 | 3.09% | 5.83 | 6.12 | 5.83 |
Aug 31, 2023 | 5.84 | -0.11 | -1.85% | 5.95 | 6.00 | 5.80 |
Aug 30, 2023 | 5.94 | 0.02 | 0.34% | 5.92 | 5.99 | 5.85 |
Aug 29, 2023 | 5.94 | -0.39 | -6.16% | 6.33 | 6.33 | 5.81 |
Aug 28, 2023 | 6.37 | 0.48 | 8.15% | 5.89 | 6.47 | 5.88 |
Aug 25, 2023 | 5.94 | 0.09 | 1.54% | 5.85 | 6.03 | 5.71 |
PDS Biotechnology Corporation Events
Time (UTC) | Country | Event |
---|---|---|
Monday, November 13, 2023 | ||
Time (UTC) 13:30 | Country US
| Event Q3 2023 PDS Biotechnology Corp Earnings Release Q3 2023 PDS Biotechnology Corp Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | ||||
Total Operating Expense | 41.6724 | 21.4393 | 14.9024 | 7.70005 | 43.0966 |
Selling/General/Admin. Expenses, Total | 12.2414 | 10.1848 | 6.96233 | 8.91149 | 15.0205 |
Research & Development | 29.431 | 11.2545 | 7.92445 | 6.09958 | 16.0688 |
Operating Income | -41.6724 | -21.4393 | -14.9024 | -7.70005 | -43.0966 |
Interest Income (Expense), Net Non-Operating | -0.38134 | 0.00435 | 0.05501 | 0.31993 | -0.55338 |
Other, Net | 0 | 0 | |||
Net Income Before Taxes | -42.0538 | -21.435 | -14.8474 | -7.38012 | -43.6499 |
Net Income After Taxes | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
Net Income Before Extra. Items | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
Net Income | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
Income Available to Common Incl. Extra. Items | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
Diluted Net Income | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
Diluted Weighted Average Shares | 28.5992 | 25.5971 | 16.745 | 4.86808 | 1.56211 |
Diluted EPS Excluding Extraordinary Items | -1.42853 | -0.66095 | -0.88667 | -1.43765 | -26.1621 |
Diluted Normalized EPS | -1.42853 | -0.66095 | -0.85692 | -2.41384 | -21.1658 |
Total Extraordinary Items | 0 | ||||
Unusual Expense (Income) | 0 | -7.31102 | 12.0073 | ||
Depreciation / Amortization | 0.01561 | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 12.6962 | 9.42241 | 18.8214 | 7.2792 | 7.09265 |
Selling/General/Admin. Expenses, Total | 4.69132 | 3.57873 | 2.66627 | 2.92621 | 3.33101 |
Research & Development | 8.00485 | 5.84369 | 16.1551 | 4.35299 | 3.76165 |
Operating Income | -12.6962 | -9.42241 | -18.8214 | -7.2792 | -7.09265 |
Interest Income (Expense), Net Non-Operating | -0.24475 | -0.23751 | -0.14525 | 0.07455 | |
Net Income Before Taxes | -12.9409 | -9.65992 | -19.1377 | -7.42445 | -7.01811 |
Net Income After Taxes | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
Net Income Before Extra. Items | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
Net Income | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
Income Available to Common Excl. Extra. Items | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
Income Available to Common Incl. Extra. Items | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
Diluted Net Income | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
Diluted Weighted Average Shares | 30.8025 | 30.428 | 29.0379 | 28.4587 | 28.4516 |
Diluted EPS Excluding Extraordinary Items | -0.37448 | -0.31747 | -0.65906 | -0.26089 | -0.20453 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.37448 | -0.31747 | -0.65906 | -0.26089 | -0.20453 |
Other, Net | -0.31633 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 76.4804 | 66.8402 | 30.3372 | 14.4702 | 35.6511 |
Cash and Short Term Investments | 73.8202 | 65.2426 | 28.8396 | 12.1617 | 34.6455 |
Cash & Equivalents | 73.8202 | 65.2426 | 28.8396 | 12.1617 | 34.6455 |
Prepaid Expenses | 2.66023 | 1.59757 | 1.49767 | 2.30846 | 1.00559 |
Total Assets | 77.0079 | 67.1979 | 30.8904 | 14.4913 | 36.221 |
Property/Plant/Equipment, Total - Net | 0.52753 | 0.3577 | 0.55315 | 0.02105 | 0.42695 |
Property/Plant/Equipment, Total - Gross | 0.64295 | 0.47303 | 0.66313 | 0.11542 | 0.87862 |
Accumulated Depreciation, Total | -0.11542 | -0.11533 | -0.10998 | -0.09437 | -0.45166 |
Other Long Term Assets, Total | 0 | 0.14287 | |||
Total Current Liabilities | 9.82104 | 3.75603 | 3.27045 | 2.79355 | 6.38175 |
Accounts Payable | 1.21929 | 1.3094 | 1.41522 | 1.19772 | 0.39945 |
Accrued Expenses | 8.54514 | 2.44663 | 1.85523 | 1.09764 | 0.38616 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.05661 | 0 | |||
Other Current Liabilities, Total | 0 | 0.49819 | 5.59614 | ||
Total Liabilities | 33.0059 | 3.98746 | 3.7608 | 2.79355 | 6.38175 |
Total Long Term Debt | 23.1849 | 0 | 0 | 0 | 0 |
Long Term Debt | 23.0208 | 0 | 0 | ||
Total Equity | 44.002 | 63.2104 | 27.1296 | 11.6977 | 29.8392 |
Common Stock | 0.00996 | 0.00939 | 0.00735 | 0.00174 | 0.01059 |
Additional Paid-In Capital | 145.55 | 123.905 | 70.9073 | 40.6337 | 222.645 |
Retained Earnings (Accumulated Deficit) | -101.558 | -60.7036 | -43.7851 | -28.9377 | -192.816 |
Total Liabilities & Shareholders’ Equity | 77.0079 | 67.1979 | 30.8904 | 14.4913 | 36.221 |
Total Common Shares Outstanding | 30.1703 | 28.4486 | 22.2616 | 5.28124 | 1.5725 |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Other Liabilities, Total | 0 | 0.23143 | 0.49035 | 0 | |
Capital Lease Obligations | 0.16401 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 67.9734 | 76.4804 | 74.4113 | 55.7426 | 60.7305 |
Cash and Short Term Investments | 65.1994 | 73.8202 | 71.6424 | 52.9847 | 58.8811 |
Cash & Equivalents | 65.1994 | 73.8202 | 71.6424 | 52.9847 | 58.8811 |
Prepaid Expenses | 2.77399 | 2.66023 | 2.76891 | 2.75791 | 1.84941 |
Total Assets | 68.4486 | 77.0079 | 74.8868 | 56.0008 | 61.0388 |
Property/Plant/Equipment, Total - Net | 0.47526 | 0.52753 | 0.47542 | 0.25819 | 0.30833 |
Total Current Liabilities | 4.12954 | 9.82104 | 4.84114 | 4.51592 | 5.01849 |
Accounts Payable | 2.07206 | 1.21929 | 2.03739 | 1.87799 | 2.74571 |
Accrued Expenses | 2.00537 | 8.54514 | 2.74248 | 2.63793 | 2.27278 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 27.4377 | 33.0059 | 27.8279 | 4.57557 | 5.16547 |
Total Long Term Debt | 23.3081 | 23.1849 | 22.9868 | 0 | 0 |
Other Liabilities, Total | 0 | 0 | 0.05965 | 0.14698 | |
Total Equity | 41.0109 | 44.002 | 47.0588 | 51.4252 | 55.8734 |
Common Stock | 0.01014 | 0.00996 | 0.00939 | 0.00939 | 0.00939 |
Additional Paid-In Capital | 152.219 | 145.55 | 129.47 | 126.412 | 125.041 |
Retained Earnings (Accumulated Deficit) | -111.218 | -101.558 | -82.4207 | -74.9963 | -69.1771 |
Total Liabilities & Shareholders’ Equity | 68.4486 | 77.0079 | 74.8868 | 56.0008 | 61.0388 |
Total Common Shares Outstanding | 30.7236 | 30.1703 | 28.4587 | 28.4587 | 28.4509 |
Current Port. of LT Debt/Capital Leases | 0.05211 | 0.05661 | 0.06127 | ||
Long Term Debt | 23.1428 | 23.0208 | 22.9097 | ||
Capital Lease Obligations | 0.16529 | 0.16401 | 0.07713 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
Cash From Operating Activities | -25.7097 | -12.4861 | -13.1491 | -18.0735 | -33.1533 |
Cash From Operating Activities | 0.04908 | 0.00536 | 0.01561 | 0.09841 | 0.17435 |
Non-Cash Items | 10.6211 | 4.35124 | 0.61297 | -6.22017 | 10.9689 |
Cash Interest Paid | 0.85222 | 0 | 1.05117 | ||
Changes in Working Capital | 4.47498 | 0.07582 | 1.06967 | -4.5716 | -3.4285 |
Cash From Investing Activities | 0 | 29.3815 | 0 | ||
Capital Expenditures | 0 | ||||
Cash From Financing Activities | 34.2872 | 48.8891 | 29.827 | 0.75 | -20.2688 |
Financing Cash Flow Items | -0.72029 | -0.99 | |||
Issuance (Retirement) of Stock, Net | 10.0075 | 48.8891 | 29.827 | 0.75 | 0.7212 |
Issuance (Retirement) of Debt, Net | 25 | 0 | -20 | ||
Net Change in Cash | 8.57754 | 36.4031 | 16.6778 | 12.058 | -53.4221 |
Deferred Taxes | 0 | -0.38151 | |||
Cash Taxes Paid | 0 | ||||
Other Investing Cash Flow Items, Total | 0 | 29.3815 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -9.65992 | -40.8549 | -21.7172 | -14.2927 | -8.47352 |
Cash From Operating Activities | -13.1886 | -25.7097 | -18.1808 | -12.2879 | -6.36901 |
Cash From Operating Activities | 0.01411 | 0.04908 | 0.0375 | 0.00009 | 0.00009 |
Non-Cash Items | 2.26257 | 10.6211 | 4.07542 | 2.59809 | 1.18923 |
Changes in Working Capital | -5.8054 | 4.47498 | -0.57652 | -0.59332 | 0.9152 |
Cash From Financing Activities | 4.56786 | 34.2872 | 24.5806 | 0.02992 | 0.00749 |
Issuance (Retirement) of Stock, Net | 4.58852 | 10.0075 | 0.02992 | 0.02992 | 0.00749 |
Net Change in Cash | -8.62078 | 8.57754 | 6.39982 | -12.2579 | -6.36152 |
Cash Interest Paid | 0.96685 | 0.85222 | 0.0625 | ||
Financing Cash Flow Items | -0.72029 | -0.44933 | |||
Issuance (Retirement) of Debt, Net | -0.02067 | 25 | 25 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
PDS Biotechnology Corporation Company profile
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.Industry: | Bio Therapeutic Drugs |
25B Vreeland Road
Suite 300
FLORHAM PARK
NEW JERSEY 07932
US
Income Statement
- Annual
- Quarterly
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com